Abstract 4442
Background
Real-world (rw) evidence derived from electronic health records (EHRs) is being explored for use as a comparator to single arm clinical trials in oncology. While RECIST is a standard for assessing tumor response in trials, alternative approaches are needed in rw cohorts. Our objective was to examine whether rwRR derived from abstracted “real-world tumor response” (rwTR) might perform similarly to RECIST-based response rates in a variety of settings to support assessments of drug efficacy.
Methods
We focused on randomized clinical trials supporting FDA approvals in aNSCLC between 2015-2017 (4 trials, 5 arms). We selected rw cohorts of aNSCLC patients from de-identified Flatiron Health EHR-derived database by applying the eligibility criteria of each trial as feasible, following an established internal process; trials were considered infeasible for comparison and not reported when fewer than 30 eligible rw patients were identified at the time of analyses. rwTR was abstracted from unstructured clinical notes and was based on the treating oncologist’s assessment of disease change (e.g., partial response) indicated by imaging at each point of radiographic disease evaluation. We compared the rwRRs observed in rw cohorts to objective response rates (ORRs) from trials.
Results
rw cohorts included 862 patients, and clinical trial cohorts (2 control arms and 3 experimental arms) included 701 patients, see response rates in the table (all except ALEX were confirmed RRs).Table:
1581P
Trial | Trial arm | ORR | rwRR |
---|---|---|---|
CheckMate-017 | E: Nivolumab / 2L+ squamous | 20% (27/135) | 25% (17/68) |
CheckMate-057 | E: Nivolumab / 2L+ nonsquamous | 19% (56/292) | 17% (51/294) |
KEYNOTE-021 | E: Carboplatin, Pembrolizumab, Pemetrexed/ 1L nonsquamous | 55% (33/60) | 42% (37/88) |
KEYNOTE-021 | C: Carboplatin and Pemetrexed/ 1L nonsquamous | 29% (18/63) | 34% (101/294) |
ALEX | C: Crizotinib/ 1L | 75% (114/151) | 68% (80/118) |
Conclusions
Data curated from EHRs of rw patients with aNSCLC can provide estimates of response rates that are comparable to RECIST-based response rates observed in similar patient populations studied in clinical trial settings. These findings demonstrate the potential of leveraging rw cohorts as a comparator to single arm clinical trials in oncology.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Flatiron Health, Inc.
Funding
Flatiron Health Inc., independent subsidiary of the Roche group.
Disclosure
X. Ma: Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group.: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche. N.C. Nussbaum: Shareholder / Stockholder / Stock options, Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group.: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche. K. Magee: Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche. A.B. Bourla: Shareholder / Stockholder / Stock options, Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche. M. Tucker: Shareholder / Stockholder / Stock options, Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group.: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche. L. Bellomo: Shareholder / Stockholder / Stock options, Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche. C. Bennette: Shareholder / Stockholder / Stock options, Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group.: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche.
Resources from the same session
4852 - Impact of routine screening and preemptive treatment on hepatitis B virus reactivation (HBVr) in patients receiving chemotherapy
Presenter: Celine Marty
Session: Poster Display session 1
Resources:
Abstract
5225 - The uptake, patient satisfaction and efficacy of scalp cooling among patients receiving chemotherapy in an Irish oncology day ward.
Presenter: William Maher
Session: Poster Display session 1
Resources:
Abstract
1901 - Placebo adverse events (AEs) in targeted and immune cancer therapy in the adjuvant and advanced setting: A systematic review and meta-analysis
Presenter: Diego Enrico
Session: Poster Display session 1
Resources:
Abstract
3258 - Reduced antibody levels and high seronegativity rates against vaccine preventable diseases pose a risk factor for infections in patients with solid and hematologic cancers
Presenter: Angela Guzek
Session: Poster Display session 1
Resources:
Abstract
3211 - Prognostic Factors Influencing Outcome After Therapy With Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin's Lymphoma
Presenter: Veselina Goranova - Marinova
Session: Poster Display session 1
Resources:
Abstract
4949 - Phase I Study of CC-90010 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)
Presenter: Victor Moreno
Session: Poster Display session 1
Resources:
Abstract
2271 - Pretreatment coagulation factors related to prognosis in patients with natural killer/T cell lymphoma
Presenter: Yue Chai
Session: Poster Display session 1
Resources:
Abstract
4335 - Diffuse large B cell lymphoma in the elderly. A retrospective analysis of standard versus alternative treatments
Presenter: Irene Sillero
Session: Poster Display session 1
Resources:
Abstract
5117 - MIPI as a superior prognostic tool in Mantle Cell Lymphoma compared to monocyte-lymphocyte, neutrophil-lymphocyte and platelet-lymphocyte ratios
Presenter: Filipa Macedo
Session: Poster Display session 1
Resources:
Abstract
5135 - Dose adjustment of chemotherapy in aggressive lymphoma using automated and standardized analysis and evaluation of DNA double strand breaks
Presenter: Julia Schröder
Session: Poster Display session 1
Resources:
Abstract